Partners Group to Buy Majority Stake in Biotech FairJourney Biologics
By Elena Vardon
Partners Group Holding said it will buy a majority stake in antibody research organization FairJourney Biologics.
The Swiss private-equity firm didn't disclose the size of the investment but said that GHO Capital Partners, who it is buying the stake from, will remain a minority stakeholder and that founder Antonio Parada will also keep a significant shareholding.
FairJourney Biologics partners with pharmaceutical and biotechnology companies to develop antibody-based therapies.
According to a report from the Financial Times on Sunday, the deal values FairJourney Biologics at around 900 million euros ($964.4 million).
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
July 01, 2024 02:31 ET (06:31 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
13 Charts On the Market’s Q2 Turnaround
-
10 Top-Performing Dividend Stocks of Q2 2024
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations
-
Real Estate: Interest Rate Movements Drive Performance
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities